<DOC>
	<DOCNO>NCT00598273</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy peginesatide treatment anemia participant chronic kidney disease , dialysis erythropoiesis stimulate agent ( ESA ) treatment .</brief_summary>
	<brief_title>Safety &amp; Efficacy Peginesatide Treatment Anemia Participants With Chronic Renal Failure Not Dialysis</brief_title>
	<detailed_description>Anemia associate chronic kidney disease due several factor , primarily inability diseased kidney produce adequate amount endogenous erythropoietin . Ancillary factor include shorten lifespan red blood cell , iron nutritional deficiency , infection , inflammation . The presence severity anemia related duration extent kidney failure . Anemia associate increased mortality , increase likelihood hospitalization , reduce cognitive function , increase leave ventricular hypertrophy heart failure . Erythropoiesis stimulate agent establish treatment anemia chronic renal failure subject , improve management anemia alternative transfusion . Peginesatide parenteral formulation develop treatment anemia patient chronic kidney disease . Peginesatide bind activate human erythropoietin receptor stimulate erythropoiesis human red cell precursor manner similar know erythropoiesis-stimulating agent . Study participant receive dos peginesatide administer every 4 week darbepoetin alfa administer every 2 week . Total commitment time study 4 week screen period follow minimum 52 week study treatment . Eligible participant randomize equal proportion two peginesatide treatment regimens one control , darbepoetin alfa , treatment regimen . To evaluate cardiovascular safety peginesatide , cardiovascular composite safety endpoint ( CSE ) define use prospectively plan analysis combine cardiovascular safety data four Phase 3 peginesatide study ( NCT00598273 , NCT00597753 , NCT00598442 , NCT00597584 ) . The CSE consist six event : death , stroke , myocardial infarction , serious adverse event congestive heart failure , unstable angina , arrhythmia . An independent Event Review Committee ( ERC ) use provide blind adjudication potential CSE event .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>1 . Chronic renal failure estimate glomerular filtration rate &lt; 60 milliliter per minute per 1.73m^2 expect begin dialysis least 12 week . 2 . Two consecutive hemoglobin value ≥ 8.0 g/dL &lt; 11.0 g/dL within 4 week prior randomization . 1 . Females pregnant breastfeeding . 2 . Treatment ESA 12 week prior randomization . 3 . Known intolerance ESA , parenteral iron supplementation , pegylated molecule . 4 . Prior chronic hemodialysis chronic peritoneal dialysis treatment . 5 . Known bleed coagulation disorder . 6 . Known hematologic disease cause anemia renal disease 7 . Poorly control hypertension 8 . Evidence active malignancy within one year prior randomization . 9 . A scheduled kidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal failure</keyword>
	<keyword>CRF</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
	<keyword>ESA</keyword>
	<keyword>Hematide™</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>Hb</keyword>
	<keyword>Hgb</keyword>
	<keyword>Omontys</keyword>
	<keyword>peginesatide</keyword>
	<keyword>red blood cell</keyword>
	<keyword>red blood cell production</keyword>
</DOC>